Preimplantation Genetic Diagnosis: A Hope for Families with Cystic Fibrosis

For couples who both carry the gene for cystic fibrosis (CF), the chance of having a child with the disease is approximately 25%. Preimplantation genetic diagnosis (PGD) offers a potential path to having a healthy child by screening embryos created through in vitro fertilization (IVF) for the CFTR gene mutation before implantation. While ethically complex, PGD is now a legally available option in many countries, including Germany and the United States, offering a beacon of hope for affected families.

Understanding Cystic Fibrosis and Genetic Inheritance

Cystic fibrosis is an autosomal recessive genetic disorder caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene [1]. This gene controls the movement of salt and water in and out of cells. When both parents carry a mutated CFTR gene, their child has a 25% chance of inheriting two mutated genes and developing CF, a 50% chance of being a carrier like the parents, and a 25% chance of inheriting two normal genes.

What is Preimplantation Genetic Diagnosis (PGD)?

PGD is a technique used in conjunction with IVF to identify genetic defects in embryos. Here’s how it works:

1. IVF: Eggs are retrieved from the mother and fertilized with sperm in a laboratory.
2. Embryo Development: The fertilized eggs develop into embryos.
3. Biopsy: A small number of cells are carefully removed from each embryo, typically on day 3 or day 5 of development.
4. Genetic Testing: The cells are tested for the specific CFTR gene mutation.
5. Embryo Transfer: Only embryos that are free of the CFTR mutation are implanted into the mother’s uterus.

It’s important to note that PGD does not guarantee a completely healthy child. It only screens for the specific genetic mutation tested. Other genetic abnormalities are not detected [2].

The Ethical Considerations of PGD

PGD raises significant ethical questions. Concerns include whether it is morally permissible to select embryos based on their genetic makeup, the potential for “designer babies,” and the discarding of embryos that are not selected. These debates continue to shape the legal and regulatory landscape surrounding PGD.

Current Legal Status

As of 2026, PGD is legally permitted in Germany, while it is subject to strict regulations [2]. It is also legal in many other countries, including the United States, with varying degrees of regulation.

The Role of CFTR in Cystic Fibrosis-Related Diabetes

Recent research highlights the complex relationship between CFTR mutations and the development of cystic fibrosis-related diabetes (CFRD). Studies suggest that dysfunction of CFTR in pancreatic islet cells may contribute to CFRD, even independent of pancreatic insufficiency [3]. This understanding is evolving, with ongoing research exploring the precise mechanisms involved.

Key Takeaways

• PGD offers a potential option for couples at risk of having a child with cystic fibrosis.
• PGD involves screening embryos created through IVF for the CFTR gene mutation.
• PGD raises ethical considerations regarding embryo selection and genetic manipulation.
• The legal status of PGD varies by country.
• Research continues to uncover the role of CFTR in the development of CFRD.